News

Category — GS Paper 3 ///Published — 2026-07-03 ///Exam — Both Prelims and Mains ///Tags — Biotechnology, Pharmaceutical Regulation, Healthcare ///Category — GS Paper 3 ///Published — 2026-07-03 ///Exam — Both Prelims and Mains ///Tags — Biotechnology, Pharmaceutical Regulation, Healthcare ///

News · GS Paper 3

India Strengthens Regulation of Advanced Medical Therapies

The Centre has amended the Drugs Rules, 1945 to bring cell/stem cell-derived products, gene therapeutic products, and xenografts under the Centrally License Approving Authority (CLAA) framework. This expansion strengthens patient safety, ensures uniform regulatory standards across states, and promotes India's alignment with global best practices in regulating cutting-edge medical technologies like CAR-T cell therapies and gene-editing treatments.

2026-07-03

Published

—

Source

Quiz Questions

Article

Background and Context

The Central Government recently amended the Drugs Rules, 1945 to strengthen the regulatory framework for advanced medical technologies. This amendment brings three new categories of products under the Centrally License Approving Authority (CLAA) framework:

Cell/Stem Cell-derived Products
Gene Therapeutic Products
Xenografts

Centrally License Approving Authority (CLAA)

The CLAA functions under the Central Drugs Standard Control Organization (CDSCO) and is empowered by the Drugs and Cosmetics Act, 1940. It serves as a joint licensing mechanism ensuring:

Uniform regulation and oversight of critical drugs and biological products
Collaborative efforts between Central and State Licensing Authorities
Standardized quality, safety, and efficacy across all states

Previously Covered Categories

Before this amendment, CLAA regulated:

Vaccines
Large volume parenterals (IV solutions >100 ml)
Recombinant DNA (r-DNA) medicines

Expanded Categories Under CLAA

Cell/Stem Cell-derived Products

Stem cell-based regenerative therapies
CAR-T cell therapies – used primarily for treating blood cancers such as leukemia and lymphoma

Gene Therapeutic Products

Gene replacement therapies
Gene-editing therapies – applied in treatment of genetic disorders and several types of cancers

Xenografts

Animal tissue-derived products transplanted into humans
Examples include heart valves
Widely used in cardiology and orthopedics

Need for Enhanced Regulation

These advanced therapies involve:

Complex and specialized technologies
Rapidly evolving medical innovations
Significant patient safety implications

Significance for India

Strengthens India's regulatory framework for advanced medical technologies
Aligns with global best practices in pharmaceutical and biological regulation
Promotes innovation in healthcare sector
Facilitates safe and timely adoption of cutting-edge medical technologies
Ensures patient safety through stricter oversight
Establishes uniform national standards across all states

Related Framework

The amendment works in conjunction with schemes like the Biopharma SHAKTI Scheme, which promotes indigenous manufacturing of pharmaceutical products and strengthens India's biopharmaceutical ecosystem.